web analytics

The Fascinating Story of RLF-100 (aviptadil); Relief Therapeutics Holding SA (OTCMKTS: RLFTF)

1

Relief Therapeutics Holding SA (OTCMKTS: RLFTF) is exploding up the charts and emerging as a volume leader after the Company announced RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.

At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies.

Relief Therapeutics Holding SA (OTCMKTS: RLFTF) focuses primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis.  Relief Therapeutics also holds a U.S. patent1 for RLF-100 and proprietary manufacturing processes for its synthesis. The stock is listed on the SIX Swiss Exchange under the symbol RLF.

RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. Last week the FDA granted Relief Therapeutics Holding AG and its U.S. partner NeuroRX, Inc. Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). This action makes the treatment available to patients who have exhausted standard therapies and are not eligible for the current Phase 2/3 clinical trial of RLF-100 due to confounding medical conditions and specifically makes the treatment available to pregnant women. This drug is still under investigation (it is not approved), however due to the rapid recovery from respiratory failure in COVID-19 seen under the FDA Emergency Use authorization. This expanded access protocol can be viewed here.

On August 2 Relief Therapeutics Holdings AG and its US partrer, NeuroRx, Inc. announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted.

To Find out the inside Scoop on Relief Therapeutics Holding Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RLFTF

The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.  Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697.

The clinical findings may be based on evidence that VIP inhibits the replication of the SARS-CoV-2 virus in human lung cells and immune cells (monocytes). The work was reported by Brazilian researchers working in a level-4 biocontainment laboratory.3 The same researchers reported a case-control study in which patients who survived being on ventilators for COVID-19 had significantly higher levels of VIP in their blood than those who died of respiratory failure.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading higher RLFTF is an exciting story developing in small caps; the stock is exploding up the charts and emerging as a volume leader after the Company announced RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.  We will be updating on RLFTF on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with RLFTF.

Share.

1 Comment

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.